Drug Repositioning Discovery for Early- and Late-Stage Non-Small Cell Lung Cancer

ASIA unversity > 資訊學院 > 生物資訊與醫學工程學系 > 期刊論文 > Item 310904400/87040

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/87040

题名:	Drug Repositioning Discovery for Early- and Late-Stage Non-Small Cell Lung Cancer
作者:	Chien-Hung Huang;Peter Mu-Hsin Chang;Yong-Jie Lin;Cheng-Hsu Wang;Chi-Ying F. Huang;Ka-Lok Ng
贡献者:	生物與醫學資訊學系
日期:	2014-08
上传时间:	2014-11-13 07:01:29 (UTC+0)
摘要:	Drug repositioning is a popular approach in the pharmaceutical industry for identifying potential new uses for existing drugs and accelerating the development time. Non-small-cell lung cancer (NSCLC) is one of the leading causes of death worldwide. To reduce the biological heterogeneity effects among different individuals, both normal and cancer tissues were taken from the same patient, hence allowing pairwise testing. By comparing early- and late-stage cancer patients, we can identify stage-specific NSCLC genes. Differentially expressed genes are clustered separately to form up- and downregulated communities that are used as queries to perform enrichment analysis. The results suggest that pathways for early- and late-stage cancers are different. Sets of up- and downregulated genes were submitted to the cMap web resource to identify potential drugs. To achieve high confidence drug prediction, multiple microarray experimental results were merged by performing meta-analysis. The results of a few drug findings are supported by MTT assay or clonogenic assay data. In conclusion, we have been able to assess the potential existing drugs to identify novel anticancer drugs, which may be helpful in drug repositioning discovery for NSCLC.
關聯:	JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY;2014:193817.
显示于类别:	[生物資訊與醫學工程學系 ] 期刊論文

文件中的档案:

档案	大小	格式	浏览次数
index.html	0Kb	HTML	460	检视/开启

在ASIAIR中所有的数据项都受到原著作权保护.

数据加载中.....